Skip to content

Feasibility of micuronium chloride in maintaining deep muscle relaxation during Laparoscopy -- an observational clinical study

Feasibility of micuronium chloride in maintaining deep muscle relaxation during Laparoscopy -- an observational clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073782
Enrollment
Unknown
Registered
2023-07-20
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep muscle relaxation

Interventions

micuronium chloride+neostigmine group (M group):None
rocuronium+sulbactam group (R group):None

Sponsors

Zhongda Hospital,Affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Patients aged 18-65 years old; ? ASA (American Society of Anesthesiologists) classification I-III; ? 18.5 kg/?<BMI (Body mass index)<28 kg/?; ? No Contraindication of Laparoscopy; ? The estimated surgical time is between 1-4 hours.

Exclusion criteria

Exclusion criteria: ? Patients with severe renal dysfunction requiring dialysis or creatinine clearance rate less than 30 milliliters per minute; Patients with severe liver function impairment (Child Pugh grade C) or liver function impairment accompanied by coagulation disorders; ? Patients with epilepsy, angina pectoris, ventricular tachycardia, mechanical Bowel obstruction or urinary tract obstruction, asthma, severe arrhythmia, sinus bradycardia or Vagus nerve tension elevation; ? Neuromuscular system disease; ? Pregnant and lactating women, women with pregnancy expectations in the next 3 months; ? Patients with muscle relaxation monitoring sites that have trauma, surgical history, or infection that affect muscle relaxation detection; ? Malignant hyperthermia tendency; ? Suspected individuals with abnormal plasma cholinesterase activity; ? Patients who have participated in other drug clinical studies within the past 30 days and have been included in this study have been re admitted.

Design outcomes

Primary

MeasureTime frame
Residual rate of muscle relaxation;

Secondary

MeasureTime frame
MAP.HR.SPO2;Dosage of vasoactive drugs;Time from discontinuation of muscle relaxants to extubation and post anesthesia monitoring treatment (PACU) residence time;VAS and sedation scores during PACU;

Countries

China

Contacts

Public ContactJin Wang

Department of Anesthesiology, Zhongda Hospital, Southeast University

wangjin7980@126.com+86 138 1386 0408

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026